Global At-home Covid-19 Diagnostic Test Kit Market Size Likely to Grow at a CAGR of 3.37% By 2035

As per the at-home Covid-19 diagnostic test kit market analysis conducted by the CMI team, the at-home Covid-19 diagnostic test kit market is expected to record a CAGR of 3.37% from 2026 to 2035. In 2026, the market size was USD 8.34 Billion. By 2035, the valuation is anticipated to reach USD 11.24 Billion.

At-home Covid-19 Diagnostic Test Kit Market Revenue and Trends

The at-home Covid-19 diagnostic test kit market is expected to witness linear progression due to a visible switch to multiplex respiratory panels that help in simultaneous screening for Flu, Covid-19, and RSV. Also, AI-powered smartphone readers’ integration improves precision of result by close to 20%.

What are the Factors That Have a Significant Contribution to the Growth of the At-home Covid-19 Diagnostic Test Kit Market?

One of the factors significantly contributing to the growth of at-home Covid-19 diagnostic test kit market is switch to decentralized healthcare coupled with adoption of multiplex panels for simultaneously detecting multiple respiratory viruses. Evolution to endemic management from pandemic response does encourage the demand for actionable, faster diagnostics within the households.

Technological advancements, especially integration of digital platforms powered by AI, improve diagnostic precision and associate results to the telemedicine systems. Moreover, conducive regulatory frameworks, public health initiatives, and government stockpiling are contributing to market expansion.

Segment Insights

By Test Type

Immunoassays lead the market due to low operational costs, ease of use, and immediate results from rapid antigen tests in home care settings. Rapid antigen tests for infectious disease diagnosis, seasonal allergies, and cancer are becoming increasingly popular, which is anticipated to support product adoption.

Compared to the other segments, the multiplex respiratory panels segment is predicted to have the fastest CAGR during the forecast period. These multiplex tests for syndromic diagnosis, which detect multiple pathogens at once, are frequently used in home settings. In order to get ready for pandemics, there is a strong focus on developing multipathogen tests for COVID-19, Influenza A/B, and RSV. The market for multiplex panel tests is both - driving new trends and expanding the industry by delivering clinical value through differentiation between respiratory viruses during tripledemic surges.

By Specimen Type

Nasopharyngeal (NP) swabs dominate the market as they continue to be the "gold standard" for clinical accuracy, providing the lowest false-negative rates and highest viral concentrations for RT-PCR assays. On the other hand, the saliva segment is witnessing the fastest CAGR due to its ease of self-collection without medical oversight, non-invasive nature, and increasing adoption in high-frequency screening environments such as workplaces and schools. This growth is further propelled by consumer preference for painless testing and the development of innovative infrared and molecular platforms that offer rapid, lab-quality results from saliva.

By Distribution Channel

Retail pharmacies are leading the at-home COVID-19 test kit market. This is attributed to their abundance. Retail pharmacies such as CVS Health and Walgreens hold the major market share. People trust these stores. They can buy kits, get advice from professionals, and the other health services - all in one place. On the other hand, certain websites that sell these kits to people on the direct basis are growing fast. They are expected to keep growing at a decent rate until 2035. This is because people want to take care of their health in an exclusive and affordable way. They prefer buying kits like the ones from Everlywell or LetsGetChecked directly from the companies that make them. They can also use their phones for getting the results and talk to a doctor if need be.

By Demographics

The older people are using the at-home COVID-19 test kits at a higher frequency as they are more prone to COVID-19 due to their system not working as well and they often have the other health problems like diabetes and high blood pressure. Older people like to use these test kits at home so they do not have to go to the doctor’s office and get tired/sick further. On the other hand, children are using these test kits as parents want to make sure their children are healthy and safe and they do not want to catch any problems. Parents prefer test kits that use saliva. These are easier to use on children and very important for schools to check if children are healthy.

Regional Insights

North America is leading the at-home COVID-19 diagnostic kit market. This is because it has a good healthcare system with a sizable spending on healthcare and houses bellwethers like Abbott and QuidelOrtho. The governments of North America are also preparing for emergencies people are aware of regarding the usage of products. On the other hand, the Asia Pacific region is growing fast as it is densely populated and economies like China and India are building new hospitals and clinics. Local companies are making cost diagnostic kits and governments are investing in primary care. Also many people are using health tools, like smartphone readers that use AI for public health.

Report Scope

Recent Developments

• In January 2022, Roche Diagnostics India launched a Covid-19 at-home test. It implies an OTC (over-the-counter) test designed to detect SARS-CoV-2 infection in those showing Covid-19 symptoms.

List of the prominent players in the At-home Covid-19 Diagnostic Test Kit Market:

• Abbott Laboratories

• Roche Diagnostics

• iHealth Labs

• QuidelOrtho

• ACON Laboratories

• Siemens Healthineers

• Lucira Health

• LetsGetChecked

• Everlywell

• Others

The At-home Covid-19 Diagnostic Test Kit Market is segmented as follows:

By Test Type

• Rapid Antigen Tests (Immunoassays)

• Molecular Tests (At-home PCR/NAAT)

• Multiplex Respiratory Panels)

By Specimen Type

• Nasal Swabs

• Saliva

• Nasopharyngeal (NP) Swabs)

By Distribution Channel

• Retail Pharmacies

• Online/e-Commerce

• Direct-to-Consumer (DTC) Platforms

By Demographics

• Adults

• Geriatric

• Pediatric

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America